Durable Remission after Splenectomy for Waldenström's Macroglobulinemia with Massive Splenomegaly in Leukemic Phase

References

• Humphrey J.S., Conley C.L. Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature. Am. J. Hematol. 1995; 48: 262–266
   PubMed Web of Science ®Google Scholar
• Drew P.A., Kiroff G.K., Fenante A., Cohen R.C. Alterations in immunoglobulin synthesis by peripheral blood mononuclear cells from splenectomized patients with and without splenic regrowth. J. Immunol. 1984; 132: 191–196
   PubMed Web of Science ®Google Scholar
• Nitsche D., Thiede A., Zierott G. Postoperative Veränderungen der Immunglobuline nach Splenektomie: eine prospektive Untersuchungsreihe. Langenbecks Arch. Chit. 1976; 340: 213–218
   PubMedGoogle Scholar
• Hosea S.W., Burch C.G., Brown E.J., Berg R.A., Frank M.M. Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine. Lancet 1981; 1: 804–807
   PubMed Web of Science ®Google Scholar
• Wang W.C., Herrod H.G., Valenski W.R., Wyatt R.J. Lymphocyte and complement abnormalities in splenectomized patients with hematologic disorders. Am. J. Hemtol. 1988; 28: 239–245
   PubMed Web of Science ®Google Scholar
• Müller Ch., Mannhalter J.W., Ahmad R., Zlabinger G., Wurnig P., Eibl M.M. Peripheral blood mononuclear cells of splenectomized patients are unable to differentiate into immunoglobulin-secreting cells after pokeweed mitogen stimulation. Clin. Immunol. Immunopathol. 1984; 31: 118–123
   PubMedGoogle Scholar
• Lozzio B.B., Wargon L.B. Immune competence of hereditarily asplenic mice. Immunology 1974; 27: 167–178
   PubMed Web of Science ®Google Scholar
• Rozing J., Brons N. H. C., Benner R. Effects of splenectomy on the humoral immune system: a study in neonatally and adult splenectomized mice. Immunology 1978; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Krolick K.A., Isakson P.C., Uhr J.W., Vitetta E.S. Murine B cell leukemia (BCL1): organ distribution and kinetics of growth as determined by fluorescence analysis with an anti-idiotypic antibody. J. Immunol. 1979; 123: 1928–1935
   PubMed Web of Science ®Google Scholar
• Warnke R.A., Slavin S., Coffman R.L., Butcher E.C., Knapp M.R., Strober S., Weissman I.L. The pathology and homing of a transplantable murine B cell leukemia (BCL1). J. Immunol. 1979; 123: 1181–1188
   PubMed Web of Science ®Google Scholar
• Slavin S., Morecki S., Weiss L. The role of the spleen in tumor growth kinetics of the murine B cell leukemia (BCL1). J. Immunol. 1980; 124: 586–589
   PubMed Web of Science ®Google Scholar
• Pilarski L.M., Andrews E.J., Serra H.M., Ledbetter J.A., Ruether B.A., Mant M.J. Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenström's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance. Am. J. Hematol. 1989; 30: 53–40
   PubMed Web of Science ®Google Scholar
• Ricci C., Cascio G., Anania A., Marchi L., Verney M.M. The clinical and cellular aspects of Waldenström's macroglobulinaemia. Arch. Geschwulstforsch. 1988; 58: 267–274
   PubMedGoogle Scholar
• Hsu S-M., Cossman J., Jaffe E.S. Lymphocyte subsets in normal human lymphoid tissues. Am. J. Clin. Pathol. 1983; 80: 21–30
   PubMed Web of Science ®Google Scholar
• Hellström I., Hellström K.E., Sjögren H.O. Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas. Cell. Immunol. 1970; 1: 18–30
   PubMedGoogle Scholar
• Treves A.J., Cohen I.R., Feldman M. Suppressor factor secreted by T-lymphocytes from tumorbearing mice. J. Nafl. Cancer Inst. 1976; 57: 409–414
   PubMed Web of Science ®Google Scholar
• Subramanian C., Yu S., McKhann C.F. Soluble suppressor factor from the spleens of tumor-bearing mice. Cancer Res. 1978; 38: 1996–2002
   PubMed Web of Science ®Google Scholar
• Hellström I., Sjögren H.O., Warner G., Hellström K.E. Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms. Int. J. Cancer 1971; 7: 226–237
   PubMed Web of Science ®Google Scholar
• Kanayama H., Hamazoe R., Osaki Y., Sbimizu N., Maeta M., Koga S. Immunosuppressive factor from the spleen in gastric cancer patiebts. Cancer 1985; 56: 1963–1966
   PubMed Web of Science ®Google Scholar
• Sjögren H.O., Hellstöm I., Bansal S.C., Warner G.A., Hellström K.E. Elution of “blocking factors” from human tumors, capable of abrogating tumor-cell destruction by specifically immune lymphocytes. Int. J. Cancer 1972; 9: 274–283
   PubMed Web of Science ®Google Scholar
• Orita K., Konaga E., Okada T., Kunisada K., Yumura M., Tanaka S. Effect of splenectomy in tumor-bearing mice and gastric cancer patients. Gann 1977; 68: 731–736
   PubMedGoogle Scholar
• Takemori N., Hirai K., Onodera R., Saito N., Watanabe S., Namiki M. Splenectomy followed by local injections of interferon-a is effective for treating cutaneous-type adult T-cell leukaemia/lymphoma. Br. J. Dermatol. 1993; 129: 746–747
   PubMed Web of Science ®Google Scholar